

March 14, 2018

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached press release issued by the Company titled:

“Strides Shasun receives USFDA Approval for Efavirenz Tablet”

Thanks and Regards
For Strides Shasun Limited

Sd/-
Manjula Ramamurthy
Company Secretary





Press Release
March 14, 2018

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076

Strides Shasun receives USFDA Approval for Efavirenz Tablet

Product approval under the para IV route

Bangalore, March 14, 2018 Strides Shasun Limited today announced that it's wholly owned subsidiary Strides Pharma Global Pte. Limited has received approval for ***Efavirenz Tablets USP, 600 mg*** from the United States Food & Drug Administration (US FDA). Efavirenz Tablet is generic version of Sustiva Tablets of Bristol-Myers Squibb Company.

According to IQVIA data, the US market for ***Efavirenz Tablets USP, 600 mg*** is approximately USD 115 Million and Strides is only the second generic company to get the approval for the product under the para IV route. The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market. Strides is launching the product immediately.

The company has 74 cumulative ANDA filings with USFDA of which 44 ANDAs have been approved as of date and 30 are pending approval.

About Efavirenz

Efavirenz Tablet is indicated for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults and adolescents.

About Strides Shasun

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has three business verticals, viz., Regulated Markets, Emerging Markets and Active Pharmaceutical Ingredients.



The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<u>Strides:</u> Shashank Sinha, Managing Director +91 80 6784 0335 <u>Investors:</u> Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791 Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: investors@stridesshasun.com	<u>PR Consultancy:</u> Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.com K Priya: +91 95354 25418 priya@fortunapr.com
--	---

